title: Association between apolipoprotein E epsilon4 and neuropsychiatric symptoms during interferon alpha treatment for chronic hepatitis C.
abstract: Neuropsychiatric complications are common in patients with chronic hepatitis C undergoing treatment with interferon alpha. These side effects include alterations of mood, cognition, and neuroendocrine function and are unpredictable. In a number of neurological disorders characterized by neuropsychiatric symptoms and cognitive dysfunction, inheritance of an apolipoprotein E (APOE) epsilon4 allele is associated with adverse neuropsychiatric outcomes. The authors present evidence that the APOE genotype may influence a patient's neuropsychiatric response to interferon alpha treatment. The inheritance of APOE genotypes was examined in 110 patients with chronic hepatitis C treated with interferon alpha. A retrospective investigation was conducted by assessing the rates of psychiatric referral and neuropsychiatric symptoms experienced during treatment along with other complaints indicating psychological distress. A highly statistically significant association was seen between APOE genotypes and interferon-induced neuropsychiatric symptoms. Patients with an epsilon4 allele were more likely to be referred to a psychiatrist and had more neuropsychiatric symptoms during antiviral treatment than those without an epsilon4 allele. Additionally, patients with an epsilon4 allele were more likely to experience irritability or anger and anxiety or other mood symptoms. These data demonstrate that an individual's APOE genotype may influence the neuropsychiatric response to antiviral therapy with interferon alpha. Prospective studies evaluating the importance of APOE in susceptibility to interferon alpha-induced neuropsychiatric complications are needed. Moreover, pathways involving APOE should be considered in understanding the pathophysiology of interferon alpha-induced neuropsychiatric complications.
authors.affiliation: Department of Surgery and Psychiatry, Univerity of Queensland, Brisbane, Australia.
authors.forename: Peter A
authors.initials: PA
authors.lastname: Gochee
authors.forename: Elizabeth E
authors.initials: EE
authors.lastname: Powell
authors.forename: David M
authors.initials: DM
authors.lastname: Purdie
authors.forename: Nirmala
authors.initials: N
authors.lastname: Pandeya
authors.forename: Livia
authors.initials: L
authors.lastname: Kelemen
authors.forename: Claudia
authors.initials: C
authors.lastname: Shorthouse
authors.forename: Julie R
authors.initials: JR
authors.lastname: Jonsson
authors.forename: Brian
authors.initials: B
authors.lastname: Kelly
mesh_terms: D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001007:Anxiety / Q000139:chemically induced; D053327:Apolipoprotein E4; D001057:Apolipoproteins E / Q000235:genetics*; D003071:Cognition / Q000187:drug effects; D005260:Female; D005838:Genotype; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000235:genetics; D006579:Heterozygote; D006801:Humans; D016898:Interferon-alpha / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D001523:Mental Disorders / Q000139:chemically induced / Q000235:genetics; D008875:Middle Aged; D011110:Polymorphism, Genetic; D012189:Retrospective Studies
chemical_list: D000998:Antiviral Agents; D053327:Apolipoprotein E4; D001057:Apolipoproteins E; D016898:Interferon-alpha